Levodopa and Parkinson Disease—Myths Revisited

To the Editor Espay and Lang¹ present a thought provoking Viewpoint regarding levodopa therapy in Parkinson disease (PD).¹ We respectfully submit that its subtitle “When Clinical Trials Misinform Clinical Practice” is not justified. If levodopa has come into disrepute in the past, and dopamine agonist monotherapy has been left unsupplemented by levodopa for too long, this is not because of misinformation that was provided by the comparative clinical trials themselves, but rather by the inadequate translation of study results into clinical practice.